Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity

被引：26

作者：

Roohipoor, Ramak ^{[1
]}

Karkhaneh, Reza ^{[1
]}

Riazi-Esfahani, Mohammad ^{[1
,2
]}

Farahani, Afsar Dastjani ^{[1
]}

Khodabandeh, Alireza ^{[1
]}

Adib, Nazanin Ebrahimi ^{[1
]}

Imani, Marjan ^{[1
]}

Jafari, Hassan Khojasteh ^{[1
]}

Riazi-Esfahani, Hamid ^{[1
]}

Hosseinpour, Jamaleddin ^{[1
]}

Zarei, Mohammad ^{[1
]}

Ghasemi, Hamed ^{[1
]}

Mirghorbani, Masoud ^{[1
]}

Yaseri, Mehdi ^{[1
]}

Davoudi, Samaneh ^{[3
]}

Modjtahedi, Bobeck S. ^{[4
,5
]}

机构：

[1] Univ Tehran Med Sci, Farabi Eye Hosp, Eye Res Ctr, Qazvin Sq,South Karegar St, Tehran, Iran

[2] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA USA

[3] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA

[4] Southern Calif Permanente Med Grp, Dept Ophthalmol, Baldwin Pk, CA USA

[5] Kaiser Permanente Southern Calif, Eye Monitoring Ctr, Baldwin Pk, CA USA

来源：

OPHTHALMOLOGY RETINA | 2018年 / 2卷 / 09期

关键词：

D O I：

10.1016/j.oret.2018.01.017

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To compare the outcomes of patients with type I retinopathy of prematurity (ROP) treated with either intravitreal bevacizumab (IVB) or retinal laser photocoagulation (RLP). Design: Retrospective case series. Participants: Infants treated for type I ROP with IVB or RLP. Methods: Patients who were born between January 2011 and December 2014 and were treated in Farabi Eye Hospital were included. The outcomes were stratified and analyzed, based on the treatment type and ROP zone. Main outcome measures: Need for retreatment, time to regression, refractive errors, retinal adverse anatomic outcomes, and rate of complications. Results: Five hundred twenty-three patients were treated for type 1 ROP, of whom 493 (986 eyes) met inclusion criteria. Seven hundred twenty-four eyes (73.4%) received IVB, and 262 eyes (26.5%) received RLP. Re-treatment (because of recurrent or persistent retinopathy) occurred in 14.4% (106/724) of eyes initially treated with IVB and in 8.8% (23/262) eyes initially treated with RLP (P = 0.065). Re-treatment was not significantly different between the 2 groups for patients with zone I disease (P = 0.978). Re-treatment rate was considerably higher in patients with zone II disease treated with IVB (69/558 [12.3%]) compared with those treated with RLP (20/251 [7.9%]; P = 0.017). In the IVB group, 82.8% and 53.4% of eyes showed an avascular area in zone III (despite ROP regression) at 1 and 2 years after treatment, respectively. The spherical power and the spherical equivalent were significantly higher in eyes treated with RLP (-1.31 +/- 2.83 diopters [D] and -2.84 +/- 2.77 D, respectively) than eyes treated with IVB (0.19 +/- 3.21 D and -1.26 +/- 3.19 D, respectively; P = 0.016 and P = 0.007, respectively). Differences in astigmatic power were not significant. Conclusions: Both IVB and RLP are effective treatments for type 1 ROP. Longer follow-up time is necessary for infants treated with IVB. More patients with zone II disease treated with RLP achieved disease regression after a single treatment than those who received IVB, although outcomes after re-treatment were comparable except for a greater refractive error in patients treated with RLP. (C) 2018 by the American Academy of Ophthalmology

引用

页码：942 / 948

页数：7

共 29 条

[1] Screening for Retinopathy of Prematurity in South of Iran [J].

Afarid, Mehrdad ;

Hosseini, Hamid ;

Abtahi, Bagher .

MIDDLE EAST AFRICAN JOURNAL OF OPHTHALMOLOGY, 2012, 19 (03) :277-281

[2] Clinical outcome of confluent laser photoablation for retinopathy of prematurity [J].

Fallaha, N ;

Lynn, MJ ;

Aaberg, TM ;

Lambert, SR .

JOURNAL OF AAPOS, 2002, 6 (02) :81-85

[3] Outcomes after laser therapy for threshold retinopathy of prematurity [J].

Foroozan, R ;

Connolly, BP ;

Tasman, WS .

OPHTHALMOLOGY, 2001, 108 (09) :1644-1646

[4] Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment A Randomized Clinical Trial [J].

Geloneck, Megan M. ;

Chuang, Alice Z. ;

Clark, W. Lloyd ;

Hunt, Michael G. ;

Norman, Alan A. ;

Packwood, Eric A. ;

Tawansy, Khaled A. ;

Mintz-Hittner, Helen A. .

JAMA OPHTHALMOLOGY, 2014, 132 (11) :1327-1333

[5] Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey [J].

Gunay, Murat ;

Sukgen, Emine Alyamac ;

Celik, Gokhan ;

Kocluk, Yusuf .

CURRENT EYE RESEARCH, 2017, 42 (03) :462-469

[6] Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity [J].

Hartnett, M. Elizabeth .

OPHTHALMOLOGY, 2015, 122 (01) :200-210

[7] Mechanisms and Management of Retinopathy of Prematurity [J].

Hartnett, M. Elizabeth ;

Penn, John S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (26) :2515-2526

[8] Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity A 5-Year Retrospective Analysis [J].

Hwang, Christopher K. ;

Hubbard, G. Baker ;

Hutchinson, Amy K. ;

Lambert, Scott R. .

OPHTHALMOLOGY, 2015, 122 (05) :1008-1015

[9] Outcomes of a Protocol-Based Management for Zone 1 Retinopathy of Prematurity: The Indian Twin Cities ROP Screening Program Report Number 2 [J].

Jalali, Subhadra ;

Kesarwani, Siddharth ;

Hussain, Anjli .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 151 (04) :719-724

[10] Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity [J].

Karkhaneh, Reza ;

Khodabande, Alireza ;

Riazi-Eafahani, Mohammad ;

Roohipoor, Ramak ;

Ghassemi, Fariba ;

Imani, Marjan ;

Farahani, Afsar Dastjani ;

Adib, Nazanin Ebrahimi ;

Torabi, Hamidreza .

ACTA OPHTHALMOLOGICA, 2016, 94 (06) :E417-E420

← 1 2 3 →